Advertisement
Advertisement

ALKS

ALKS logo

Alkermes Inc. plc

34.23
USD
Sponsored
-0.30
-0.87%
Apr 20, 16:00 UTC -4
Closed
exchange

After-Market

34.13

-0.10
-0.30%

ALKS Earnings Reports

Positive Surprise Ratio

ALKS beat 32 of 41 last estimates.

78%

Next Report

Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$367.20M
/
-$0.58
Implied change from Q4 25 (Revenue/ EPS)
-4.51%
/
-307.14%
Implied change from Q1 25 (Revenue/ EPS)
+19.80%
/
-323.08%

Alkermes Inc. plc earnings per share and revenue

On Feb 25, 2026, ALKS reported earnings of 0.28 USD per share (EPS) for Q4 25, missing the estimate of 0.34 USD, resulting in a -16.95% surprise. Revenue reached 384.55 million, compared to an expected 390.62 million, with a -1.56% difference. The market reacted with a -7.04% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of -0.58 USD, with revenue projected to reach 367.20 million USD, implying an decrease of -307.14% EPS, and decrease of -4.51% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
logo
NovaBridge Biosciences - ADR
Report Date
Apr 07, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.28
Surprise
-421.58%
logo
KALA BIO, Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$1.46
Actual
-$0.67
Surprise
+54.38%
logo
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
logo
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
logo
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
logo
GeoVax Labs, Inc. New
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$6.29
Actual
$0.00
Surprise
+99.92%
FAQ
For Q4 2025, Alkermes Inc. plc reported EPS of $0.28, missing estimates by -16.95%, and revenue of $384.55M, -1.56% below expectations.
The stock price moved down -7.04%, changed from $33.39 before the earnings release to $31.04 the day after.
The next earning report is scheduled for Apr 29, 2026.
Based on 9 analysts, Alkermes Inc. plc is expected to report EPS of -$0.58 and revenue of $367.20M for Q1 2026.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement